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OBJECTIVE: Estimate the burden of IBS comparing
resource use between IBS-patients (IBSp) and non-IBS
subjects(controls) during a 1-year follow up. METHODS:
Observational, prospective study including 517 IBSp,
meeting Rome II criteria, and 84 controls. Controls were
selected from those subjects who had attended a health
centre due to digestive problems (excluding IBS). Both
samples were selected from the consulting ofﬁces of 92
Spanish gastroenterologists and Primary Care Physicians.
IBSp and controls attended a total of 5 visits at 3 month
intervals. During ﬁrst month after each visit patients
recorded drug utilization and indirect resource in a
diarycard. Direct resource was collected by investigators
in follow-up medical controls. RESULTS: Mean patients
age (SD) was 43 (14) years and 75% were female. No dif-
ferences in age and gender were observed between IBSp
and controls. 90% of IBSp and 100% of controls visited
a clinic at least once (p < 0.01), but only IBSp (52%) did
it due to abdominal pain. Hospitalizations were registered
in 7.5% of IBSp and 2.9% of controls. Thirty-eight
percent of IBSp and 15% of control were assisted in an
emergency guard at least once (p < 0.01); abdominal pain
was the main reason for IBSp to attend the emergency
guard (11%). 43% of IBSp required some speciﬁc test 
due to their abdominal pathology (blood samples, gas-
troscopy or colonoscopy). Mean patient cost associated
with resources used was much higher in IBSp (€413.39)
than in controls (€143.94) (p < 0.01). In terms of indirect
resources, 59% of IBSp and 26% of controls experienced
limited or reduced performance at work (p < 0.01). Mean
patient cost associated with absence from work at one
year was also much higher for IBSp (€502.21€) than for
controls (€109.70) (p < 0.01). CONCLUSIONS: This
prospective 1-year follow-up study conﬁrms that IBS is
associated with an important burden in terms of direct
and indirect costs and that IBSp use more health resources
and experience higher productivity loss compared with
non-IBS.
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OBJECTIVE: The primary objective of this multicenter,
randomised, open study was to assess the difference in
direct medical costs incurred over a 6-months period with
a 20mg esomeprazole on-demand maintenance strategy,
compared to a 20mg q.d. continuous therapy. Secondary
objectives were to assess GERD symptoms and to
measure patient satisfaction during the maintenance
phase. METHODS: In total, 2884 patients with uninves-
tigated GERD entered the study and received esomepra-
zole 40mg q.d for 4 weeks. At the end of the acute treat-
ment phase 93% patients were symptom free (complete
resolution of heartburn or not more than 1 day with mild
heartburn during the last 7 days prior to the visit), 
and were randomised to receive either continuous or 
on-demand treatment (esomeprazole 20mg) during a 
6-month maintenance phase (1315 and 1325 patients
respectively). Analyses were performed on an intention to
treat basis. Direct costs include study, OTC and other
GERD medication, unscheduled visits and GERD tests.
RESULTS: The proportion of patients heartburn free at
6 months was signiﬁcantly higher (p < 0.001) in the con-
tinuous treatment with esomeprazole 20mg (86.1%) than
in the on demand group (78.0%). Patient’s satisfaction
reached 94% after the 4 weeks acute treatment and
remained 92% in the maintenance phase, similar in both
groups. Both treatment arms were well tolerated. Mean
daily direct costs were signiﬁcantly lower (P < 0.001) in
the on demand group (€0.96 +/- 0.54 SD) than in the
esomeprazole 20mg q.d. arm (€1.39 +/- 0.31 SD). The
proportion of patients taking GERD-related drugs was
similar in the two groups (8.0% vs 7.3%, p = 0.6). CON-
CLUSIONS: Continuous or on-demand treatment in
patients with uninvestigated GERD offer effective and
safe symptom control with a high patient satisfaction.
On-demand treatment allows signiﬁcant reduction in
medical costs. Choice of treatment should be considered
on patient basis.
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OBJECTIVES: To compare the pharmaceutical costs 
of a new proposal of reimbursement of proton pump
inhibitors (PPI) in the treatment of GERD with the
present regulation in which PPI’s are reimbursed only
when endoscopy demonstrates esophagitis. The new
reimbursement proposal includes empiric therapy
(without endoscopy), symptomatic treatment of non-
erosive GERD, and chronic “on-demand” therapy.
METHODS: A decision tree model was developed for
treatment of patients with GERD resistant to H2 recep-
tor antagonists. Calculations were performed using MS
Excel. Response rates of different therapies and proba-
bilities of ﬁndings at endoscopy were derived from liter-
ature. Costs from the payer’s perspective were calculated
for the ﬁrst 48 weeks of treatment using the mean price
of the PPI on the Belgian market on Jan 1st 2003.
RESULTS: The present reimbursement system and the
new proposal represented a mean 48 weeks cost per 
case of respectively €351 and €204. Sensitivity analysis
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revealed that the cost increased to €255 when the efﬁ-
ciency of empiric treatment rose from 67% to 80% using
a double dose during 8 weeks. The cost related to treat-
ment varied from €112 to €236 using respectively the
cheapest and the most expensive PPI; as compared to the
actual treatment this resulted in a cost decrease of respec-
tively €138 and €233. Number of days treated while on
“on-demand” therapy also signiﬁcantly inﬂuenced costs:
€171 for 1/7 and €270 for 7/7. CONCLUSIONS: The
cost reduction with the new reimbursement proposal is
robust to changes in efﬁciency rate, in PPI-price and in
duration of “on demand” therapy.
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OBJECTIVE: To compare the cost of UK licensed PPI-
based triple therapies for the eradication of H. pylori
from the perspective of the National Health Service.
METHODS: A recent meta-analysis of trials comparing
all UK licensed PPI-based triple therapies using amoxi-
cillin and clarithromycin over a 7-day period found no
signiﬁcant difference in the rate of H. pylori eradication.
Mean per patient costs were calculated by multiplying the
resource utilisation incurred by their respective national
published unit costs at year 2003 prices. To estimate the
impact of using the least expensive triple therapy on a
typical Primary Care Organisation (PCO), differences in
mean per patient cost were multiplied by the annual inci-
dence of H. pylori compared to current expenditure.
Current expenditure was based on national usage pattern
of the available treatment options. Sensitivity analysis
was conducted to assess the impact of administering
omeprazole 40mg once daily vs omeprazole 20mg twice
daily and the availability of generic omeprazole.
RESULTS: Mean per patient cost for a 7-day esomepra-
zole-based treatment regimen was £34.24, £5.03 lower
than omeprazole-, £2.58 less than lansoprazole- and pan-
toprazole-, and £2.13 lower than rabeprazole-based triple
therapies. The budget impact analysis suggests that a
typical PCO could save up to £4386 per annum if only
esomeprazole-based triple therapy were used for H. pylori
eradication. Sensitivity analyses found the results were
robust to changes in key model parameters. CONCLU-
SIONS: Esomeprazole-based triple therapy is the least
expensive treatment option for the eradication of H.
pylori licensed for use in the UK.
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OBJECTIVE: To conduct a cost consequence analysis 
of EnteryxTM procedure versus surgery (Laparoscopic
Nissen Fundoplication = LNF) in a French public hospi-
tal setting. Nissen Fundoplication is the actual technique
of reference for severe Gastro Esophageal Reﬂux Disease
(GERD) and EnteryxTM procedure is a new inject-
able, endoscopic polymer-based treatment for GERD.
METHODS: A decision tree model was built in DATATM
TreeAge 4.0 to predict the average cost and effectiveness
per patient for each of the treatment strategies. The time
horizon was one year and a French public hospital per-
spective was taken. For both strategies, the efﬁcacy crite-
rion was the complete PPI stop after one year. Efﬁcacy
data on EnteryxTM were taken from the EnteryxTM
multicenter clinical trial. Clinical outcomes with LNF
were derived from the literature and validated by a sur-
gical advisory board. Unit cost data were based on the
French DRG system (PMSI 2000). DRG costs have been
inﬂated by 2.5% and 5% to obtain current year costs. 
At 2.5% rate, procedural cost for EnteryxTM were 
estimated at €2200 (based on DRG 830—ambulatory
endoscopy with anaesthesia) and at €6300 for LNF (DRG
215, 216). RESULTS: After one year, the average cost per
patient was lower for EnteryxTM (2.5%: €3364–5%:
€3541) than for Nissen Fundoplication (2.5%: €6492
€–5%: €6800). The one way sensitivity analysis shows
that the model is most sensitive to the success rate of
EnteryxTM and to the procedural cost. CONCLUSION:
For patients eligible for surgery, EnteryxTM offers a new
less invasive and cheaper alternative compared to LNF.
The savings with EnteryxTM are mainly due to lower
hospital and procedural costs.
PGS10
COST OF ILLNESS OF GASTROESOPHAGEAL
REFLUX DISEASE (GERD) IN ITALY
Di Stasi F1,Teruzzi C2, Mantovani LG1
1University of Milan, Milan, Italy; 2Bracco, Milan, Italy
OBJECTIVES: Gastroesophageal reﬂux disease (GERD)
is one of the most common chronic disorders of the gas-
trointestinal tract. The aim of this study was to evaluate
the cost of illness in patients affected by GERD visited 
by general practitioners (GPs). METHODS: A cross-
sectional observational multicentre cost of illness study
was conducted in the urban area of Milan. Information
was obtained through a battery of four questionnaires
ﬁlled out by 317 GERD patients consecutively enrolled
by 47 GPs, investigating clinical (severity and frequency
